Innate Pharma (IPHA) - Total Liabilities
Based on the latest financial reports, Innate Pharma (IPHA) has total liabilities worth $84.39 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Innate Pharma to see how much of total assets are deployed in long-term investments.
Innate Pharma - Total Liabilities Trend (2005–2025)
This chart illustrates how Innate Pharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see IPHA total assets.
Innate Pharma Competitors by Total Liabilities
The table below lists competitors of Innate Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZenaTech Inc.
NASDAQ:ZENA
|
USA | $26.31 Million |
|
Sat Nusapersada Tbk
JK:PTSN
|
Indonesia | Rp125.64 Million |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
Germany | €68.17 Million |
|
GalaxiaMoneytree Co.Ltd
KQ:094480
|
Korea | ₩297.44 Billion |
|
Sungshin Cemen
KO:004980
|
Korea | ₩749.88 Billion |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
Germany | €17.15 Million |
|
American Well Corp
NYSE:AMWL
|
USA | $85.84 Million |
|
Samindo Resources Tbk
JK:MYOH
|
Indonesia | Rp43.11 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Innate Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Innate Pharma (IPHA) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innate Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innate Pharma (2005–2025)
The table below shows the annual total liabilities of Innate Pharma from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $84.39 Million | -17.45% |
| 2024-12-31 | $102.22 Million | -22.73% |
| 2023-12-31 | $132.29 Million | -13.94% |
| 2022-12-31 | $153.71 Million | -3.96% |
| 2021-12-31 | $160.06 Million | +5.68% |
| 2020-12-31 | $151.45 Million | -17.67% |
| 2019-12-31 | $183.94 Million | -35.23% |
| 2018-12-31 | $283.98 Million | +67.97% |
| 2017-12-31 | $169.07 Million | -13.48% |
| 2016-12-31 | $195.41 Million | -16.45% |
| 2015-12-31 | $233.89 Million | +1355.98% |
| 2014-12-31 | $16.06 Million | +3.00% |
| 2013-12-31 | $15.60 Million | -37.44% |
| 2012-12-31 | $24.93 Million | -25.54% |
| 2011-12-31 | $33.48 Million | +131.02% |
| 2010-12-31 | $14.49 Million | -15.22% |
| 2009-12-31 | $17.10 Million | -12.42% |
| 2008-12-31 | $19.52 Million | +44.10% |
| 2007-12-31 | $13.55 Million | +5.13% |
| 2006-12-31 | $12.89 Million | +174.05% |
| 2005-12-31 | $4.70 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more